Stock Track | BeiGene Soars 6% After FDA Boosts Prospects for Key Cancer Treatment

Stock Track09-27

Shares of BeiGene (BGNE) surged 6% on Thursday after the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee recognized the "favorable benefit-risk profile" of PD-1 inhibitors like the company's Tevimbra cancer treatment.

The FDA advisory committee's conclusion applied to the use of PD-1 inhibitors as a first-line treatment for patients with locally advanced inoperable or metastatic esophageal squamous cell carcinoma expressing certain specific cancer markers. The positive assessment was based on several studies of PD-1 inhibitors, including BeiGene's Tevimbra (tislelizumab-jsgr).

While Tevimbra is already approved in the U.S. for treating unresectable or metastatic esophageal squamous cell carcinoma after prior chemotherapy, the FDA's favorable view on the drug class could boost the prospects of Tevimbra getting approved for additional indications. BeiGene said the Biologics License Applications for Tevimbra remain under FDA review.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment